Abuse Potential of Sativex

Summary

This crossover study with six treatment sessions is to evaluate the abuse potential of three doses of Sativex as compared to Marinol and placebo, in subjects with a history of recreational marijuana use.

Timeline

Start

2008-02

Primary completion

2008-06

Completion

2008-06

Outcome

Mixed primary results

paper Nabiximols 10.8 mg was not significantly different from placebo on primary measures but was different on some secondary measures. PMID 21671456 ↗

paper Nabiximols 21.6 mg was significantly greater than placebo on some primary/secondary measures, whereas nabiximols 43.2 mg showed significant effects on most measures. PMID 21671456 ↗

Publications

• Results Schoedel KA, Chen N, Hilliard A, White L, Stott C, Russo E, Wright S, Guy G, Romach MK, Sellers EM. A randomized, double-blind, placebo-controlled, crossover study to evaluate the subjective abuse potential and cognitive effects of nabiximols oromucosal spray in subjects with a history of recreational cannabis use. Hum Psychopharmacol. 2011 Apr;26(3):224-36. doi: 10.1002/hup.1196.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Dronabinol	Other / unclassified	20 mg	—
Comparator	Dronabinol	Other / unclassified	40 mg	—
Subject	Nabiximols	Other / unclassified	10.8 mg	Other
Subject	Nabiximols	Other / unclassified	21.6 mg	Other
Subject	Nabiximols	Other / unclassified	43.2 mg	Other

Indications

No indication recorded.